Hangzhou Aom Pharma Completes Series B RMB 300 Million Financing; Lead Candidate Aom0498 (Adamgammadex Sodium) Advances to Phase III Clinical Trials in China and Files for IPO

Recently, Hangzhou Adamerck Pharmlabs Inc. (hereinafter referred to as “Adamerck Pharma”) completed a RMB 300 million Series B financing round. Angel investor Zhejiang Miyin Investment Management Co.,LTD and Series A investor Yuanheng Lizhen continued to increase their investments in this round, while new investorsChunshan CapitalandHomsun CapitalJoin this round of financing to support the continued growth of Hangzhou Adamerck Pharmlabs Inc.

This round of financing will be used to accelerate the R&D progress of new drugs at Hangzhou Adamerck Pharmlabs Inc., expand its new drug pipeline, and establish production bases. Specific initiatives include: Phase III clinical trials of omigrel sodium, a next-generation neuromuscular blocking agent antagonist; initiation of overseas clinical studies for new drugs; Investigational New Drug (IND) applications in China and the United States for preclinical-stage drug candidates, along with subsequent clinical studies; and construction of new drug production facilities.

Aom0498, one of Hangzhou Adamerck Pharmlabs Inc.’s key projects, is the only targeted muscle relaxant antagonist in China and one of only two globally, representing a new generation of innovative drugs in this field. The project has received continuous support from the National “Major New Drug Development” Science and Technology Special Project during the 12th Five-Year Plan, the 13th Five-Year Plan, and the 2020 cycle. Currently, Aom0498 has entered Phase III clinical trials in China and has also submitted an Investigational New Drug (IND) application to the U.S. FDA for clinical trials in the United States.

Furthermore, Hangzhou Adamerck Pharmlabs Inc. has laid out a pipeline of more than ten First-in-Class original innovative drugs in areas such as perioperative anesthesia, cardiovascular and cerebrovascular diseases, and oncology, with multiple products having entered the formal preclinical trial stage.

Dr. Qi Youmao, Chairman of Hangzhou Adamerck Pharmlabs Inc.He stated, “This round of financing has garnered favor from numerous investment institutions, reflecting their recognition of and expectations for Adamerck Pharma’s development prospects. Since its establishment, Hangzhou Adamerck Pharmlabs Inc. has adhered to the mission of ‘Medicines for Tomorrow, Health for Life,’ focusing on the research and development of novel drugs that address unmet clinical needs in anesthesia, cardiovascular and cerebrovascular diseases, oncology, and other fields. After years of relentless effort, Adamerck Pharma’s first original innovative drug, Omecron Sodium, has successfully reached its endpoints in four Phase II clinical trials and smoothly entered Phase III clinical studies. Progress on other pipeline projects is also encouraging, ushering in the dawn of success for China’s path toward original innovative drugs. We firmly believe that, with the care and strong support from governments at the provincial, municipal, and district levels, and through the high-efficiency work of the Adamerck team, China’s original first-in-class (FIC) new drugs in major medical fields will continue to enter the global pharmaceutical market, benefiting people worldwide.”

Ms. Jie Qing, General Manager of Hangzhou Adamerck Pharmlabs Inc.stated: “We sincerely appreciate the investors’ recognition of Adamerck Pharma’s past achievements and its future strategic development. Going forward, Adamerck Pharma will further advance the commercialization of its product pipeline, ultimately evolving into a globally leading international innovative pharmaceutical enterprise.”

Xu Boqin, President of Miyin Investment, an angel investment firmZhejiang Miyin Investment Management Co.,LTD stated: “Innovating new drugs is challenging, and developing ‘medicines of the future’ with a primary focus on drug safety is even more daunting. Miyin adheres to impact investing and fully endorses Adamerck’s pharmaceutical philosophy of ‘Medicines of the Future, Safeguarding Lives.’ By staying committed to innovation and adopting a unique approach in portfolio selection, Adamerck has achieved breakthroughs through its exceptional R&D capabilities. We firmly believe that Hangzhou Adamerck Pharmlabs Inc. will become an innovative pharmaceutical company with global influence.”

Yuan Heng Li ZhenUpholding the investment philosophy of “Trust Born from Belief,” following the Series A investment in Hangzhou Adamerck Pharmlabs Inc., an additional RMB 80 million was invested in its Series B financing round,Founding Partner Bian Jianxia“It is believed that under the leadership of Dr. Qi, Hangzhou Adamerck Pharmlabs Inc. has adhered to original innovation and overcome numerous challenges. Over the past two decades, the company has achieved a series of international original innovations, represented by Aom0498 (Sodium Aomekesong). With an increasingly rich pipeline, it has established a serialized and platform-based system centered on cyclodextrins. At the Omer AMCDx China Original Innovative Drug Base, continuous innovation and intelligent manufacturing are bound to flourish.”

Chunshan Capital, by seasoned Wall Street investorsMr. Xin Weilianestablished. Mr. William, the founder, believes that the participation of Chunshan Capital can provide strong support for Adamerck Pharma’s future overseas expansion.

Gao Jianming, President of Homsun Capital"We are optimistic about Aom0498's unique commercial potential as the only one of its kind in China and one of only two globally. We also recognize the value creation driven by Hangzhou Adamerck Pharmlabs Inc.'s continuous innovation, development, and product upgrades, building on the shoulders of giants. In the future, as various pipeline candidates advance into clinical trials, a platform centered on Aom0498 will be established, generating even greater value."

Hangzhou Adamerck Pharmlabs Inc., founded in 2000 by Dr. Qi Youmao, a returnee scholar with a Ph.D., is located in the Liangzhu Life Science Town in Yuhang District, Hangzhou. As a national high-tech enterprise centered on the R&D of new drugs with independent intellectual property rights, the company is dedicated to the research, development, and industrialization of innovative medicines urgently needed in clinical practice. The company holds more than 30 domestic and international invention patents, has over 10 Class I new drugs under development, and has assisted other pharmaceutical companies in completing the NMPA registration for more than 100 products.

Zhejiang Miyin Investment Management Co.,LTD, established in 2015, has four funds under management that have received participation from government guidance funds. The company practices the concept of impact investing, with a key focus on the biopharmaceutical and advanced manufacturing sectors.

Hangzhou Yuanheng Lizhen Equity Investment Management Co., Ltd., established in 2018, has continuously focused on and strategically positioned itself in the industries of intelligent manufacturing, big health, and aerospace. Its current investment portfolio includes Himalaya FM, Joulwatt Microelectronics, Sinexcel Technology, Hangzhou Adamerck Pharmlabs Inc., Lianlian Technology, and Lightelligence, among others.

Chunshan Pujiang (Shanghai) Investment Management Co., Ltd., established in 2014, collaborates with its U.S. partner fund, Spring Mountain Capital, to conduct cross-border investments, focusing on the healthcare and intelligent manufacturing sectors. Its investment portfolio includes ReNetX Bio (developing treatments for chronic, incurable spinal cord injuries [SCI]), AtlasXnomics (single-cell genomic phenotyping technology), Yale-based isoPlexis, and Canadian Solar Inc.

Homsun Private Equity Funds Management Co., Ltd., established in 2009, is a professional investment institution specializing in private equity investment. Its core team possesses extensive practical experience in investment and investment banking, with a primary focus on three major sectors: electronic information, high-end equipment, and healthcare. Notable investment cases include ASR Microelectronics (approved for IPO on the STAR Market), New Capec (300248), AMEC (688012), Xinjianglian (300850), Sinbon Intelligence (approved by the ChiNext Board), Xinba Intelligence, So-Young International (NASDAQ), Tian Guangshi (application accepted by the Hong Kong Stock Exchange), Tianjiang Pharmaceutical (acquired by a listed company), and Yihua Pharmaceutical (IPO application accepted by the STAR Market).